Gensight Biologics SA (SIGHT) - Total Liabilities

Latest as of December 2025: €33.20 Million EUR ≈ $38.81 Million USD

Based on the latest financial reports, Gensight Biologics SA (SIGHT) has total liabilities worth €33.20 Million EUR (≈ $38.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Gensight Biologics SA - Total Liabilities Trend (2012–2025)

This chart illustrates how Gensight Biologics SA's total liabilities have evolved over time, based on quarterly financial data. See Gensight Biologics SA current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Gensight Biologics SA Competitors by Total Liabilities

The table below lists competitors of Gensight Biologics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Urteste SA WAR:URT	Poland	zł16.75 Million
Wescoal Holdings Ltd JSE:SLG	South Africa	ZAC4.45 Billion
Maniker F & G Co. Ltd KQ:195500	Korea	₩42.91 Billion
Thermal Energy International Inc. V:TMG	Canada	CA$9.63 Million
Mongolia Growth Group Ltd. V:YAK	Canada	CA$3.54 Million
Eterindo Wahanatama Tbk JK:ETWA	Indonesia	Rp1.31 Trillion
Liberty TripAdvisor Holdings, Inc NASDAQ:LTRPA	USA	$2.22 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Gensight Biologics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gensight Biologics SA (SIGHT) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.39	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.33	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	4.02	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gensight Biologics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gensight Biologics SA (2012–2025)

The table below shows the annual total liabilities of Gensight Biologics SA from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	€33.20 Million ≈ $38.81 Million	-11.89%
2024-12-31	€37.68 Million ≈ $44.05 Million	-5.42%
2023-12-31	€39.83 Million ≈ $46.57 Million	-3.36%
2022-12-31	€41.22 Million ≈ $48.19 Million	+1.38%
2021-12-31	€40.66 Million ≈ $47.53 Million	+13.91%
2020-12-31	€35.69 Million ≈ $41.73 Million	+72.13%
2019-12-31	€20.74 Million ≈ $24.24 Million	+58.19%
2018-12-31	€13.11 Million ≈ $15.33 Million	+81.67%
2017-12-31	€7.22 Million ≈ $8.44 Million	+22.51%
2016-12-31	€5.89 Million ≈ $6.89 Million	-15.66%
2015-12-31	€6.98 Million ≈ $8.16 Million	+64.81%
2014-12-31	€4.24 Million ≈ $4.95 Million	+122.31%
2013-12-31	€1.91 Million ≈ $2.23 Million	+1399.90%
2012-12-31	€127.08K ≈ $148.57K	--

About Gensight Biologics SA

PA:SIGHT France Biotechnology

Market Cap

$23.49 Million

€20.09 Million EUR

Market Cap Rank

#25251 Global

#411 in France

Share Price

€0.09

Change (1 day)

+1.54%

52-Week Range

€0.08 - €0.21

All Time High

€9.58